GlassScriptPhysician profile
Brittany Thomas
NPI 1285465583
$1,068.56
in general payments reported to CMS, 2019-2025
17 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $284 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809 · Education: $260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.58 |
| Education | $259.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $296.55 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $152.41 | 2024 | Sylvant |
| Merck Sharp & Dohme LLC | $89.07 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Gilead Sciences, INC. | $87.99 | 2024 | Trodelvy |
| Genzyme Corporation | $69.09 | 2025 | |
| Daiichi Sankyo INC. | $57.11 | 2025 | Enhertu |
| Janssen Biotech, INC. | $54.58 | 2025 | Erleada, Balversa, Akeega |
| Takeda Pharmaceuticals U.S.A., INC. | $49.13 | 2025 | Ninlaro |
| Genmab U.S., INC. | $42.00 | 2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.51 | 2024-2025 | Gilotrif |
| Lilly USA, LLC | $30.71 | 2025 | Retevmo |
| Legend Biotech USA INC. | $21.73 | 2024 | |
| Genentech USA, INC. | $16.53 | 2025 | Polivy |
| Pfizer INC. | $16.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.32 | 2025 | Lynparza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $15.90 | 2025 | Xt Cdx |
| Tersera Therapeutics LLC | $14.45 | 2025 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.